Grail launches methylation-based liquid biopsy solution for cancer research in a post-diagnosis setting

By The Science Advisory Board staff writers

January 10, 2023 -- Grail on Monday announced the availability of a research-use-only offering for biopharmaceutical companies. The firm is leveraging a targeted methylation platform to analyze cell-free DNA (cfDNA) isolated from peripheral blood for cancer signal interrogation.

Potential research use cases include, but are not limited to, prognosis, minimal residual disease detection, and recurrence monitoring across different cancer types in research studies, the firm said.

The "methylation technology and bioinformatics capabilities are well suited for circulating tumor DNA analysis across the cancer continuum," Bob Ragusa, CEO at Grail, said in a statement. "The new technology solution has the versatility to be used in solid tumor research and can be customized to improve performance in specific use cases, including custom classifier development."

Grail said its research-use-only technology solution estimates tumor burden based on methyl variant allele fraction (MVAF), enabling longitudinal monitoring and surveillance solutions. Data from its studies have demonstrated analytically validated performance, as well as robust analytical sensitivity, specificity, and precision, the firm said.

The blood-only liquid biopsy approach eliminates challenges with obtaining tissue samples and avoids bias due to tumor heterogeneity or tumor escape mechanisms. The low input requirements support retrospective research studies.

Several biopharmaceutical partners have leveraged early access to the technology solution, which is now broadly available, Grail said.

Illumina releases DRAGEN v4.0 secondary analysis platform
Illumina has released Illumina Dynamic Read Analysis for Genomics (DRAGEN) v4.0 as its most accurate and comprehensive secondary analysis platform. The...
Mouse DNA methylation array seeks to accelerate high-sample-throughput studies
Scientists have developed a mouse DNA methylation array that contains more than 296,000 probes and a murine methylome atlas of 1,239 diverse cell types,...
Illumina, Merck develop new oncology assay
Illumina codeveloped a research test with Merck that assesses a new genomic signature with its TruSight Oncology 500 assay.
NanoString improves Illumina’s sequencing systems via data workflow
NanoString Technologies has released a cloud-based workflow to enable simplified data analysis for researchers using Illumina’s NextSeq 1000 and NextSeq...

Copyright © 2023

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter